Special Issue

Molecular Research and Pathological Mechanism of Leukemia

Message from the Guest Editors

Hematooncology is a field that dynamically uses new technologies in both diagnosis and treatment. The highest increase in the use of new therapies is observed in patients with blood cancers. The high effectiveness of targeted therapies and immunotherapy is associated with limiting the use of traditional chemotherapy. A personalized therapeutic approach in the treatment of leukemia is associated with a better cure/survival ratio. but it also has its limitations. Should traditional therapeutic approaches be abandoned? How can we improve the diagnosis and treatment efficiency of leukemia patients? How can we effectively eliminate leukemic stem cells? These and other questions will be answered in this Special Issue, which aims to present research in the field of pathophysiology, treatment strategies, and outcomes of leukemia, with a focus on the following:

- The molecular mechanisms involved in leukemia;
- Novel biomarkers for early leukemia diagnosis;
- New therapeutic approaches (target therapies including drug design and development).

Guest Editors

Prof. Dr. Sylwia Flis

Center for Translational Medicine, Warsaw University of Life Sciences, 100 Nowoursynowska St., 02-797 Warsaw, Poland

Prof. Dr. Mirosława Koronkiewicz

Department of Biomedical Research, National Medicines Institute, 30/34 Chelmska St., 00-725 Warsaw, Poland

Deadline for manuscript submissions

closed (31 May 2025)



Current Issues in Molecular Biology

an Open Access Journal by MDPI

Impact Factor 3.0 CiteScore 3.7 Indexed in PubMed



mdpi.com/si/183433

Current Issues in Molecular Biology Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 cimb@mdpi.com

mdpi.com/journal/cimb





Current Issues in Molecular Biology

an Open Access Journal by MDPI

Impact Factor 3.0 CiteScore 3.7 Indexed in PubMed

About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Prof. Dr. Madhav Bhatia

Department of Pathology and Biomedical Science, University of Otago, Christchurch, 2 Riccarton Avenue, P.O. Box 4345, Christchurch 8140, New Zealand

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PMC, PubMed, Embase, CAPlus / SciFinder, FSTA, AGRIS, and other databases.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.8 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the first half of 2025).

Recognition of Reviewers:

APC discount vouchers, optional signed peer review, and reviewer names are published annually in the journal.

